The next phase of psychedelic drug development may not involve psychedelics in the traditional sense.
As researchers and pharmaceutical companies explore how psychedelic compounds produce changes in brain function, a parallel field is emerging around medicines designed to reproduce some of those biological effects without causing hallucinations or other profound alterations in consciousness.
Enveric Biosciences is one of the biotechnology companies pursuing that approach.
The Nasdaq-listed company is developing what it calls neuroplastogenic medicines — small-molecule therapeutics designed to promote neuroplasticity while avoiding the hallucinogenic effects associated with classical psychedelics. Its lead candidate, EB-003, is being developed for psychiatric disorders including depression, anxiety and post-traumatic stress disorder (PTSD).
For Enveric, the proposition is relatively straightforward: if some of the therapeutic effects associated with psychedelic drugs can be separated from the psychedelic experience itself, treatment could potentially become considerably easier to deliver.
Beyond the psychedelic experience
Classical psychedelic therapies present a fundamental challenge for conventional drug development.
Compounds such as psilocybin and DMT can produce profound changes in perception, cognition and emotional state. In a therapeutic setting, those effects are potentially part of the treatment. But they also create practical and regulatory complications.
Patients may require carefully controlled dosing environments, trained clinical staff and extended periods of observation. Blinding clinical trials can also be difficult when participants can readily determine whether they have received the active drug.
A medicine that could produce therapeutic neurobiological effects without significant perceptual disruption could potentially be administered in a much more conventional pharmaceutical model.
That is the opportunity Enveric is targeting.
The company’s development strategy centres on neuroplastogens — compounds intended to promote adaptive changes in neural connections and signalling without producing the characteristic psychedelic experience.
The distinction is important. Enveric is not attempting to develop a shorter or more convenient psychedelic-assisted therapy. It is attempting to develop a different category of medicine altogether.
EB-003 is the lead programme
Enveric’s lead candidate is EB-003, a novel neuroplastogen designed to engage both the serotonin 5-HT2A and 5-HT1B receptors.
The company believes this dual mechanism could promote neuroplasticity while also influencing pathways involved in emotional and behavioural regulation. Preclinical research has produced evidence of antidepressant and anxiolytic activity, while studies have also explored its potential in PTSD.
In a preclinical PTSD model reported by the company in May 2026, a single dose of EB-003 significantly reduced context-induced freezing behaviour one hour after administration. Enveric has also reported positive results in animal models of severe chronic depression and despair.
Those findings remain preclinical. They do not demonstrate that EB-003 will be effective in humans.
That distinction is particularly important in psychedelic drug development, where compelling biological and behavioural effects in animal models still have to translate into human safety, pharmacology and clinical efficacy.
The more immediate question for Enveric is therefore whether EB-003 can successfully make the transition from laboratory research into human trials.
Moving towards the clinic
Throughout 2026, Enveric has been completing the studies required to support an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
In May, the company reported that EB-003 showed no photoreactive potential in phototoxicity testing. In June, it initiated GLP genotoxicity studies, including an Ames test and micronucleus assay, as part of its IND-enabling safety programme.
The company had previously received an FDA response to its proposed pre-IND meeting. In September 2025, Enveric said the FDA had recommended that questions raised by the company be addressed through the formal IND review process rather than a pre-IND meeting, leading the company to streamline its regulatory strategy.
The regulatory picture has since evolved. As of late July 2026, Enveric’s website lists a pre-IND FDA meeting as the next milestone for EB-003, while the company continues to advance the programme through its remaining development activities.
If the required work is completed successfully and the FDA clears the programme, EB-003 could ultimately enter first-in-human Phase 1 testing.
That would represent a significant transition for the company — but not yet evidence of clinical efficacy.
A different commercial model for psychedelic medicine
The potential appeal of a non-hallucinogenic neuroplastogen extends beyond the drug itself.
A conventional oral medicine could theoretically be prescribed and administered without the infrastructure required for psychedelic-assisted therapy. Enveric’s own development plans envisage a prescription model, with regular dosing rather than a small number of supervised psychedelic sessions.
That could have major implications for scalability.
One of the central questions surrounding psychedelic-assisted therapy is how a treatment model involving lengthy clinical sessions, specialised practitioners and significant patient monitoring can be delivered at scale.
A drug that does not require patients to undergo an altered state of consciousness could potentially fit much more easily into existing psychiatric care.
It could also make clinical trials more straightforward by reducing the difficulty of maintaining blinding between treatment and placebo groups.
None of those advantages are guaranteed. A non-hallucinogenic compound still has to demonstrate that it produces meaningful clinical benefits, that those benefits are durable and that its safety profile supports widespread use.
But the commercial proposition is clear.
The Psybrary and the broader pipeline
EB-003 is only one part of Enveric’s intellectual property strategy.
The company has built a library of patented psychedelic-inspired chemical structures through its Psybrary platform, covering compounds derived from or inspired by psychedelic and other psychoactive molecules.
Rather than attempting to take every molecule through clinical development itself, Enveric has indicated that it sees potential value in licensing or partnering some of its additional assets.
That creates a different business model from a conventional single-asset biotech.
The company can focus its limited resources on advancing EB-003 while attempting to monetise parts of its wider intellectual property portfolio through partnerships and licensing arrangements.
Enveric has continued expanding that portfolio, including patent activity around its EVM301 and EVM401 series.
Whether that intellectual property ultimately translates into meaningful commercial value remains uncertain. For a company operating at the preclinical stage, patents can provide strategic leverage, but they do not remove the fundamental risks of drug development.
A high-risk bet on the next generation of psychedelic medicines
Enveric occupies an interesting position within the psychedelic medicine landscape.
Companies such as Compass Pathways and GH Research are pursuing therapies in which the altered state produced by a psychedelic compound remains central to the treatment model. Enveric is effectively asking whether that experience can be removed altogether while preserving enough of the underlying biology to produce a therapeutic effect.
It is an ambitious proposition.
The company has yet to demonstrate the efficacy of EB-003 in humans, and the programme remains dependent on successfully completing regulatory and safety requirements before clinical development can begin.
But the underlying idea addresses one of the most important questions facing psychedelic medicine as the field moves beyond its first generation of therapies: does the therapeutic potential of psychedelics require the psychedelic experience?
If the answer ultimately proves to be no, the implications could extend well beyond Enveric.
Psychedelic-inspired medicines that retain neuroplastic effects without hallucinations could potentially be developed, prescribed and scaled much more like conventional pharmaceuticals. That would not replace psychedelic-assisted therapy, but it could create an entirely separate branch of the emerging psychedelic medicine industry.
For now, Enveric remains an early-stage biotech pursuing a high-risk hypothesis.
The next major test will not be whether EB-003 can produce an interesting effect in an animal model. It will be whether the compound can safely enter human trials — and, eventually, demonstrate that psychedelic-inspired biology can translate into meaningful treatment without the psychedelic experience itself.
